IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) („IntelGenx”), a leading oral drug delivery ... together with RedHill …
RedHill is also exploring the possibility of an initial public offering on the Tel Aviv stock exchange in early 2011 ... IntelGenx Corp. (TSX-V:IGX) (OTCBB: IGXT), for the joint development of a new drug formulation for the treatment of acute …
Business Wire
IGXT (MC $46 M)US-NDA Submission for BLOCKBUSTER Drug this month ... We don't hear much about Sales....Whats up ?????...Not sales and no profit no stock...maybe do a little cutting for a bit and just that would help..??? remember …
(OTCMKTS:IGXT) to report $-0.01 EPS on May ... They now have a Dollars 58 price target on the stock. (NYSE:JWN), 8 have Buy rating, 5 Sell and 11 Hold. The consensus price target is $34.21. (NYSE:JWN) traded down 7.52% during …
IGXT) announced today that the Company's board of directors granted options to acquire 75,000 common shares effective May 17, 2010 to one of the Company's non employee directors, Mr. Bernd Melchers. The options were granted under …
IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating drug delivery systems. The company uses its unique multiple-layer delivery system …
SAINT LAURENT, QUEBEC -- (Marketwired) -- 04/05/17 -- IntelGenx Technologies Corp. (TSX …
NASDAQ2mon
SAINT LAURENT, QC / ACCESSWIRE / July 20, 2015 / IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx ... The board of directors granted stock options to acquire 600,000 common shares under the …
The stock has "Sell" rating by Liberum Capital on Tuesday ... INTELGENX TECHNOLOGS (OTCMKTS:IGXT) had an increase of 17.16% in short interest. Architects accumulated 0% or 1,700 shares. (NASDAQ:STMP). Pub Sector …
RedHill and IntelGenx currently expect to re-submit the RIZAPORT® 505(b)(2) New Drug Application ("NDA") to the U.S. …